several articles last eighteen months i mentioned asc another potential treatment kennedy disease background kda scientific review board recommended awarding research grant chawnshang chang ph university rochester dr chang research focused developing treatment regimen kennedy disease targeting poly expanded mutant years later androscience purchased rights technology tuesday androscience nih announced grant move potential treatment research along follow link asc ninds pr newswire site read entire press release summary release found androscience corporation awarded million year milestone driven cooperative translational research grant nih develop oral treatment spinal bulbar muscular atrophy kennedy disease san diego jan prnewswire androscience corp asc based san diego california announced receiving million year milestone driven cooperative translational research grant national institute neurological disorders stroke ninds national institutes health nih joint research effort neurogenetics branch ninds asc use funding pursue development oral drug treatment spinal bulbar muscular atrophy sbma kennedy disease rare hereditary neurodegenerative disease currently approved drug available patients key pathological features sbma include progressive motor neuropathy androgen insensitivity syndrome caused distinctive mutation within androgen receptor gene asc developed unique platform therapeutic small molecule drugs selectively potently enhance degradation protein termed degradation enhancers ard enhancers given encouraging pre clinical results clear need new therapeutic option sbma patients asc excited continue advancing preclinical development promising novel drug candidate said asc president charles shih ph funding provided ninds nih significantly propel efforts validating ard enhancers disease modifying therapeutic intervention rare devastating neurodegenerative illness million cooperative translational research grant leverage expertise ninds draw upon asc innovative approach targeting mutant androgen receptor goals grant first validate orally administered ard enhancer drug efficacious sbma transgenic animal model complete preclinical toxicology safety pharmacology adme studies necessary supporting ind filing commence human clinical studies date asc provided robust proof concept data using ard enhancer compound demonstrating treatment ameliorates cardinal features sbma neuromuscular pathology restores functional activity improves survival sbma transgenic mouse model good news living kennedy disease moves another major project forward pre clinical testing phase i watching project closely